BCLI - BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy April, 09 2024 06:58 AM Brainstorm Cell Therapeutics Inc. 2024-04-09 06:58:24 ET More on BrainStorm Cell Therapeutics BrainStorm submits SPA request to FDA for Phase 3 study design Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics Historical earnings data for BrainStorm Cell Therapeutics Financial information for BrainStorm Cell Therapeutics For further details see: BrainStorm gains as FDA OKs Phase 3 trial design for ALS therapy